The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) is a huge mover today! About 1.27 million shares traded hands or 206.94% up from the average. Esperion Therapeutics Inc (NASDAQ:ESPR) has declined 19.27% since March 10, 2016 and is downtrending. It has underperformed by 26.79% the S&P500.
The move comes after 9 months positive chart setup for the $280.84M company. It was reported on Oct, 13 by Barchart.com. We have $19.95 PT which if reached, will make NASDAQ:ESPR worth $148.85 million more.
Analysts await Esperion Therapeutics Inc (NASDAQ:ESPR) to report earnings on November, 3. They expect $-0.88 earnings per share, down 54.39% or $0.31 from last year’s $-0.57 per share. After $-0.62 actual earnings per share reported by Esperion Therapeutics Inc for the previous quarter, Wall Street now forecasts 41.94% negative EPS growth.
Esperion Therapeutics Inc (NASDAQ:ESPR) Ratings Coverage
Out of 13 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 7 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 54% are positive. Esperion Therapeutics has been the topic of 30 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The rating was maintained by Chardan Capital Markets on Friday, August 7 with “Sell”. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) earned “Outperform” rating by RBC Capital Markets on Tuesday, December 15. The firm has “Buy” rating by WallachBeth Capital given on Monday, October 26. The firm has “Sell” rating by Chardan Capital Markets given on Monday, July 27. On Friday, September 4 the stock rating was downgraded by Zacks to “Hold”. RBC Capital Markets maintained Esperion Therapeutics Inc (NASDAQ:ESPR) rating on Friday, November 6. RBC Capital Markets has “Outperform” rating and $65 price target. JMP Securities maintained the shares of ESPR in a report on Wednesday, March 9 with “Market Outperform” rating. Credit Suisse downgraded the shares of ESPR in a report on Wednesday, June 29 to “Underperform” rating. The stock has “Neutral” rating given by JP Morgan on Wednesday, June 29. The rating was downgraded by RBC Capital Markets to “Sector Perform” on Wednesday, June 29.
According to Zacks Investment Research, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.”
Insitutional Activity: The institutional sentiment increased to 1.27 in Q2 2016. Its up 0.11, from 1.16 in 2016Q1. The ratio improved, as 13 funds sold all Esperion Therapeutics Inc shares owned while 24 reduced positions. 9 funds bought stakes while 38 increased positions. They now own 14.43 million shares or 7.41% less from 15.58 million shares in 2016Q1.
Fincl Bank Of New York Mellon Corp has 0% invested in the company for 62,218 shares. Gilder Gagnon Howe Ltd Limited Liability Company, a New York-based fund reported 3,830 shares. Cim Mangement owns 17,270 shares or 0.07% of their US portfolio. Vanguard accumulated 0% or 811,704 shares. Susquehanna Int Llp has 0% invested in the company for 56,644 shares. Metropolitan Life Insurance Comm Ny reported 9,258 shares or 0% of all its holdings. Equitec Proprietary Ltd has invested 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR). Teachers Advisors Incorporated owns 21,380 shares or 0% of their US portfolio. Alliancebernstein Lp last reported 31,270 shares in the company. Fny Managed Accounts Ltd Llc has invested 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR). United Service Automobile Association has invested 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR). Victory Capital Management Inc holds 0% or 242 shares in its portfolio. Dimensional Fund Advsr L P reported 25,963 shares or 0% of all its holdings. Blackrock Llc has 0% invested in the company for 6,468 shares. Tiverton Asset Management Ltd has 56,063 shares for 0.12% of their US portfolio.
More important recent Esperion Therapeutics Inc (NASDAQ:ESPR) news were published by: Fool.com which released: “Esperion Therapeutics Inc Sinks After FDA Says, “Ask Us in 2019″” on June 29, 2016, also Fool.com published article titled: “Why Esperion Therapeutics, Inc. Stock Cratered Today”, Prnewswire.com published: “Shareholder Class Action Filed Against Esperion Therapeutics, Inc. – ESPR” on January 14, 2016. More interesting news about Esperion Therapeutics Inc (NASDAQ:ESPR) was released by: Zacks.com and their article: “Esperion Therapeutics (ESPR) in Focus: Stock Jumps 18.1%” with publication date: September 21, 2016.
ESPR Company Profile
Esperion Therapeutics, Inc., incorporated on January 22, 2008, is a pharmaceutical company. The Firm is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Firm is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.